Journal: Acta Myologica
Article Title: Childhood onset limb-girdle muscular dystrophies in the Aegean part of Turkey
Figure Lengend Snippet: The muscle biopsy of the patient with the genetically confirmed LGMD2D showing no sign of dystrophy (A) and normal expression of all sarcoglycans (B, C, D, E) . The biopsy was taken at the age of 8 years.
Article Snippet: Spectrin (Novo-castra, UK, NCL-spec1), dystrophin N-terminus (Novo-castra, UK, NCL-dys3), adhalin (Novocastra, UK, NCL-a-sarc), other sarcoglycans (beta, delta, gamma; Novo-castra, UK, NCL-b-d-g-sarc), laminin alpha-2 chain (Novo-castra, UK, NCL-merosin), myotilin (Novo-castra, UK, NCL-myotilin), collagen VI (Novocastra, UK, NCL-COLL-vI), β-dystroglycan (Novocastra, UK, NCL-b-DG), HLA Class 1 (Novo-castra, UK, NCL-HLA-ABC), NCAM (ThermoScientific, CA, USA, CD56), nitric oxide synthase-1 (Novo-castra, UK, NCLNOS-1), emerin (Novo-castra, UK, NCL-emerin), caveolin 3 (Novus Biologicals, CA, USA, NB110-5029), calpain 3 (Abcam, Cambridge, UK, ab103250) and dysferlin (Novo-castra, UK, NCL-Hamlet-2) antibodies were used by standard techniques for immunohistochemical analyses.